Cardiovascular Disease And Type 2 Diabetes Endocrine Society January 24, 2022. cardiovascular disease and type 2 diabetes are chronic metabolic conditions that are caused by a combination of genetic, environmental, and lifestyle factors. modifiable risks associated with lifestyle include tobacco use and intake of high calorie and nutrient poor food consumption, along with sedentary behavior. Type 2 diabetes is the most common form of the disease, affecting 90–95% of people with diabetes. in type 2 diabetes, the body is resistant to the action of insulin, meaning it cannot use insulin properly, so it cannot carry sugar into the cells. although the body makes some insulin, it is not enough to overcome this resistance.
Cardiovascular Disease And Type 2 Diabetes Endocrine Society Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research being presented sunday at endo 2020, the endocrine society’s annual meeting in san francisco, calif. This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) principles for the management of type 2 diabetes; (2) complications centric model for the care of persons with overweight obesity; (3) prediabetes algorithm; (4) atherosclerotic cardiovascular disease risk reduction algorithm: dyslipidemia; (5) atherosclerotic cardiovascular disease risk reduction. James l. rosenzweig, ele ferrannini, scott m. grundy, steven m. haffner, robert j. heine, edward s. horton, ryuzo kawamori, primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline, the journal of clinical endocrinology & metabolism, volume 93, issue 10, 1. Primary prevention of ascvd and t2dm in patients at metabolic risk: an endocrine society* clinical practice guideline j clin endocrinol metab . 2019 sep 1;104(9):3939 3985. doi: 10.1210 jc.2019 01338.
Current And Future State Of Cardiovascular Disease And Type 2 Diabetes James l. rosenzweig, ele ferrannini, scott m. grundy, steven m. haffner, robert j. heine, edward s. horton, ryuzo kawamori, primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline, the journal of clinical endocrinology & metabolism, volume 93, issue 10, 1. Primary prevention of ascvd and t2dm in patients at metabolic risk: an endocrine society* clinical practice guideline j clin endocrinol metab . 2019 sep 1;104(9):3939 3985. doi: 10.1210 jc.2019 01338. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline j clin endocrinol metab . 2008 oct;93(10):3671 89. doi: 10.1210 jc.2008 0222. Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. recent clinical trials have demonstrated the shared pathophysiology.
Comments are closed.